A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs R-phenserine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms DISCOVER
- Sponsors QR Pharma
- 07 Jun 2017 Biomarkers information updated
- 06 Mar 2017 Status changed from not yet recruiting to recruiting.
- 03 Feb 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.